Nuedexta
Generic name: dextromethorphan and quinidine
Treatment for: Pseudobulbar Affect
Further Update on Avanir's Neurodex New Drug Application
SAN DIEGO, September 22, 2005 - Avanir Pharmaceuticals (AMEX:AVN) announced that during discussion with the U.S. Food and Drug Administration (FDA) yesterday regarding Avanir's new drug application (NDA) for Neurodex for the treatment of pseudobulbar affect (PBA), the Agency requested that the Company provide an expansion of certain summary analyses in its application to better support the new electronic data submission guidelines. The Company will be meeting with the Agency within the next few weeks to discuss the requested analyses. Based on these discussions, the Company expects that the FDA will reset the receipt date of the NDA filing to coincide with the Company's submission of this information.
"This delay is unfortunate, but we are very appreciative that the FDA is willing to work closely with us to make our application as complete and reviewable as possible," said Eric Brandt, President and CEO of Avanir.
Source: Avanir Pharmaceuticals
Posted: September 2005
Related articles
- Avanir Pharmaceuticals Announces FDA Approval of Nuedexta - November 1, 2010
- Avanir Pharmaceuticals Announces Zenvia Review Timeline Established by FDA with PDUFA Date of October 30, 2010 - May 17, 2010
- AVANIR Pharmaceuticals Submits Complete Response to FDA Approvable Letter for Zenvia in PBA - April 30, 2010
- Zenvia Phase III PBA Trial Completes Patient Enrollment - March 16, 2009
- AVANIR Pharmaceuticals Announces Conference Call to Provide Zenvia FDA Meeting Update - February 27, 2007
- Avanir Receives FDA Approvable Letter for Zenvia for the Treatment of Involuntary Emotional Expression Disorder - October 31, 2006
- FDA Informs Avanir of Revised Neurodex NDA Action Date - June 19, 2006
- Avanir's Neurodex NDA Accepted with Priority Review for Involuntary Emotional Expression Disorder - April 4, 2006
- Avanir Submits Expanded Neurodex New Drug Application for the Treatment of Involuntary Emotional Expression Disorder - January 30, 2006
- Avanir Submits NDA for Neurodex - June 30, 2005
- AVANIR Announces Submission of Rolling NDA With Priority Review for Neurodex - December 16, 2004
Nuedexta (dextromethorphan and quinidine) FDA Approval History
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
